Clinical trials: Staphylococcal Skin Infections
- Condition Staphylococcal Skin Infections
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Impetigo
Fucidin® Cream in the Treatment of Impetigo
To investigate the clinical and bacteriological efficacy of Fucidin® cream in the treatment of impetigo in paediatric patients. To assess the validity of in vitro susceptibility-testing of S.
- Trial name
- NCT00986856
- Testing
- Fucidin® cream
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 58 people
- Sponsor
- LEO Pharma
Skin Infections, Bacterial
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
- Trial name
- NCT00555061
- Testing
- Retapamulin Ointment, 1%
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Skin Infections, Bacterial
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.
- Trial name
- NCT00133874
- Testing
- SB-275833 ointment, 1%
- Where
- 69 sites in Canada, Costa Rica and 8 more
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Impetigo
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
This is a randomized, double-blind study comparing 0.1% NVC-422, 0.5% NVC-422 and 1.5% NVC-422 topical gel in children with impetigo.
- Trial name
- NCT01367314
- Testing
- NVC-422
- Where
- 2 sites in Dominican Republic
- Volunteers
- 129 people
- Sponsor
- NovaBay Pharmaceuticals, Inc.
Skin Infections, Bacterial
ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
This is an open label, multi-centre, non-interventional post-marketing surveillance.
- Trial name
- ALTARGOPMS (NCT01445600)
- Testing
- ALTARGO(retapamulin)
- Where
- South Korea
- Volunteers
- 3,612 people
- Sponsor
- GlaxoSmithKline
Impetigo
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.
- Trial name
- NCT00133848
- Testing
- SB-275833 ointment, 1%
- Where
- 22 sites in India, Italy and 3 more
- Volunteers
- 210 people
- Sponsor
- GlaxoSmithKline
Non-bullous Impetigo
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
The purpose of this study is to determine the efficacy of the topical antibiotic LTX-109 in terms of clinical and microbiological response in treatment of impetigo.
- Trial name
- NCT01803035
- Testing
- LTX-109 1 %, LTX-109 2 %
- Where
- 2 sites in Dominican Republic
- Volunteers
- 210 people
- Sponsor
- Lytix Biopharma AS
Impetigo
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary nonbullous or bullous impetigo.
- Trial name
- NCT03429595
- Testing
- ATx201, ATx201 GEL Vehicle
- Where
- 16 sites in South Africa
- Volunteers
- 210 people
- Sponsor
- UNION therapeutics
Impetigo
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
This is multicenter, randomised, placebo controlled, parallel, blinded (double-blind for ozenoxacin versus placebo comparison and investigator blinded for retapamulin versus placebo comparison), superiority clinical study…
- Trial name
- NCT01397461
- Testing
- retapamulin 1% ointment, ozenoxacin 1% cream
- Where
- 19 sites in Germany, South Africa
- Volunteers
- 465 people
- Sponsor
- Ferrer Internacional S.A.
Impetigo, Secondarily Infected Traumatic Lesions
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen…
- Trial name
- NCT00626795
- Testing
- TD1414 2% cream, Bactroban® (mupirocin) 2% cream
- Where
- 2 sites in United States, South Africa
- Volunteers
- 773 people
- Sponsor
- LEO Pharma
Acne Vulgaris II or III Degree, Boils
Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir
To measure the efficacy of Taro Elixir compare with Oxytetracycline in the treatment of boils or acne.
- Trial name
- E01GOU-INH0109 (NCT01032499)
- Testing
- oxytetracycline, taro elixir, Taro Elixir
- Where
- 4 sites in Brazil
- Volunteers
- 120 people
- Sponsor
- Laboratorios Goulart S.A.
Staphylococcal Skin Infections, Streptococcal Infections
A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age
This study will assess the pharmacokinetics (how drugs are absorbed, distributed in the body and removed over time) and safety of a single dose of ceftobiprole in pediatric patients undergoing treatment with systemic antibiotics…
- Trial name
- NCT01026636
- Testing
- Ceftobiprole
- Volunteers
- 64 people
- Sponsor
- Basilea Pharmaceutica
Impetigo
EU PV for Retapamulin-Prescribing
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of impetigo and…
- Trial name
- NCT01153828
- Testing
- Retapamulin, Co-prescription of retapamulin and topical mupirocin, Co-prescription of retapamulin and topical fusidic acid
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Skin Infections, Bacterial
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
- Trial name
- NCT00852540
- Testing
- Retpamulin Ointment, 1%, Linezolid
- Where
- 53 sites in United States
- Volunteers
- 410 people
- Sponsor
- Stiefel, a GSK Company
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by…
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
- Trial name
- NCT02814916
- Testing
- Dalbavancin, Vancomycin, Oxacillin
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 199 people
- Sponsor
- AbbVie
Impetigo
Safety and Efficacy of Mupirocin Gel in Children With Impetigo
The purpose of the study is to show non inferiority in terms of safety and efficacy of topical administration BID (Twice daily) of Mupirocin Gel 20 mg/g compared to topical administration of Mupirocin Ointment 20 mg/g TID (three…
- Trial name
- NCT04287777
- Testing
- Mupirocin gel, Mupirocin ointment
- Where
- 20 sites in Spain
- Volunteers
- 467 people
- Sponsor
- Reig Jofre Group
Impetigo
Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
Impetigo is a common, highly infectious skin disease caused by bacterial infection and characterized by crusting skin lesions. It is most common in children, particularly children in unhealthy living conditions.
- Trial name
- NCT01171326
- Testing
- Topical Minocycline Foam FXFM244
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Vyne Therapeutics Inc.
Impetigo
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
This study will be a multicenter, randomized, vehicle controlled, parallel, group, double blind study. Eligible subjects with a clinical diagnosis of impetigo will be randomized to one of four treatment groups: 1.5% CD07223…
- Trial name
- NCT01670032
- Testing
- Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID
- Where
- 13 sites in United States, South Africa
- Volunteers
- 328 people
- Sponsor
- NovaBay Pharmaceuticals, Inc.
Staphylococcus Aureus, Atopic Dermatitis
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder, with a lifetime prevalence of 15-25% in children and 1-3% in adults worldwide.
- Trial name
- NCT05092464
- Testing
- Natural Lactic Acid-enriched Cream
- Volunteers
- 10 people
- Sponsor
- Microbio Co Ltd
Impetigo
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.
- Trial name
- NCT02090764
- Testing
- Ozenoxacin
- Where
- Puerto Rico
- Volunteers
- 412 people
- Sponsor
- Ferrer Internacional S.A.